Page 206 - Aet News Today

Read about executive hires across healthcare and life science companies and organizations such as ProofPilot, Genentech, MassBio, Virgin Pulse, and more.

Crescendo Health recently launched with a $3.4 million initial investment. The startup provides clinical researchers with software tools that make it easier to gather study participants' longitudinal health data.

Eisai Alzheimer’s disease drug Leqembi is now approved for the treatment of patients with an early form of the memory-robbing disease. In granting the antibody accelerated approval, the FDA employed reasoning that was the also basis for the controversial speedy regulatory nod for Biogen’s drug, Aduhelm.

Tim Barry, CEO of VillageMD, is encouraged by the shift he's seeing to value-based care, but is worried that new technologies could create a fragmented system. He made these comments after the value-based company announced Thursday that it completed its $8.9 billion acquisition of Summit Health-City MD.

The new app allows users to seek all of Teladoc's services — such as primary care, mental health and chronic condition management — in one spot. It is also offered in both Spanish and English.

The donation will go to the One Albuquerque Fund for its project called "The Gateway." This project will create a new medical center that will provide emergency overnight beds and other services for those experiencing homelessness.

Through the partnership, food and meals will be offered as a service on HealthAlign’s marketplace. Season Health will provide those services to about 5,500 members a month of three out of the six largest Medicare Advantage plans.

Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.

Boston-based medical device company AVS recently raised $20 million in Series B funding to bring its arterial disease treatment closer to FDA clearance. The system that AVS is developing uses pressure waves to shatter calcium that has built up in arteries.

Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.